BELKIN Vision is developing an automated, fast glaucoma laser device, aimed at revolutionizing accessibility to glaucoma care worldwide.
BELKIN Vision is developing an automated, fast glaucoma laser treatment, aimed at revolutionizing accessibility to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient, all over the world.BELKIN Vision is addressing the growing disparity between the enormous number of glaucoma patients (67M) and the limited number of ophthalmologists (212,000), by enabling the doctor to treat many more patients quickly. BELKIN’s innovative technology is applicable for the prevalent Open Angle Glaucoma (OAG, 70% of total glaucoma patients) and it will pioneer laser treatment for Angle Closure Glaucoma (ACG, 30%), which is most common among Asian populations. • The innovative solution provides treatment that is patient friendly - non-invasive, non-contact, instantaneous & painless. • BELKIN Laser has the opportunity to completely transform the conventional glaucoma treatment from a specialized procedure performed mainly by glaucoma specialists, into a treatment that is effective, safe and reliable which can be carried out by all ophthalmologists and other healthcare providers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 20, 2021 | Grant | €17.50M | 1 | European Innovation Council | — | Detail |
Jul 21, 2020 | Series B | $12.25M | 1 | Santen Ventures | — | Detail |
Jun 5, 2017 | Series A | $6.60M | 1 | Zicom Holdings | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Grant |
Santen Ventures | Yes | Series B |
Zicom Holdings | Yes | Series A |